NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free MRNS Stock Alerts $1.51 +0.05 (+3.07%) (As of 02:53 PM ET) Add Compare Share Share Today's Range$1.36▼$1.5750-Day Range$1.20▼$8.3852-Week Range$1.11▼$11.26Volume1.59 million shsAverage Volume1.37 million shsMarket Capitalization$82.94 millionP/E RatioN/ADividend YieldN/APrice Target$13.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Marinus Pharmaceuticals alerts: Email Address Marinus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside828.3% Upside$13.79 Price TargetShort InterestBearish9.36% of Shares Sold ShortDividend StrengthN/ASustainability-1.55Upright™ Environmental ScoreNews Sentiment0.07Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.17 out of 5 starsMedical Sector154th out of 913 stocksPharmaceutical Preparations Industry64th out of 429 stocks 4.3 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMarinus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Marinus Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.36% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently increased by 5.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarinus Pharmaceuticals has received a 60.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marinus Pharmaceuticals is -1.55. Previous Next 2.3 News and Social Media Coverage News SentimentMarinus Pharmaceuticals has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Marinus Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest17 people have searched for MRNS on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Marinus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.87) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Marinus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academyonly trade options on these 5-7 stocksI'm going to reveal the only 5-7 stocks you should be trading. But here's the secret - there's nothing special about these stocks. What matters is the repeatable options trading system I use to trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More MRNS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRNS Stock News HeadlinesJune 17 at 7:15 AM | globenewswire.comMARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.June 14 at 10:00 AM | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) InvestorsJune 14 at 7:07 AM | businesswire.comMarinus Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Their Rights in Connection with the MRNS Class Action LawsuitJune 13, 2024 | prnewswire.comMRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 13, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud LawsuitJune 13, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJune 13, 2024 | businesswire.comMRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 13, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) InvestorsJune 13, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of InvestorsJune 12, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of InvestorsJune 12, 2024 | globenewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 11, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of InvestorsJune 11, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law FirmJune 11, 2024 | globenewswire.comMRNS Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Marinus Pharmaceuticals, Inc.June 10, 2024 | globenewswire.comMARINUS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmJune 10, 2024 | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNSJune 7, 2024 | businesswire.comMarinus Pharmaceuticals Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the MRNS Class ActionJune 7, 2024 | businesswire.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Marinus Pharmaceuticals, Inc. with Losses to Contact the FirmJune 6, 2024 | globenewswire.comMARINUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmJune 6, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNSJune 6, 2024 | prnewswire.comMRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 6, 2024 | globenewswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. (MRNS)June 6, 2024 | businesswire.comMRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 6, 2024 | globenewswire.comMARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.June 6, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Marinus Pharmaceuticals, Inc. - MRNSSee More Headlines Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/17/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees165Year FoundedN/APrice Target and Rating Average Stock Price Target$13.79 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+841.0%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,400,000.00 Net Margins-513.80% Pretax Margin-519.24% Return on Equity-518.13% Return on Assets-81.85% Debt Debt-to-Equity Ratio5.68 Current Ratio3.07 Quick Ratio2.93 Sales & Book Value Annual Sales$28.29 million Price / Sales2.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book4.73Miscellaneous Outstanding Shares54,934,000Free Float51,935,000Market Cap$80.48 million OptionableOptionable Beta1.11 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Scott N. Braunstein M.D. (Age 61)CEO, President & Chairman Comp: $1.01MDr. Alex Aimetti Ph.D.Chief Scientific OfficerMs. Sonya WeigleSenior VP of Investor Relations, Human Resources & Corporate AffairsMs. Martha E. Manning Esq. (Age 69)J. D., Senior VP, General Counsel & Secretary Molly CameronDirector of Corporate Communications & Investor RelationsDr. Kimberly A. McCormick Pharm.D.Chief Regulatory & Quality Assurance OfficerMr. Thomas J. LyonsChief Business OfficerMr. David CzekaiSenior Vice President of Chemistry, Manufacturing & ControlsDr. Mark Paternoster Ph.D.Senior Vice President of DevelopmentDr. Dayong Li Ph.D.Senior Vice President of BiometricsMore ExecutivesKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTPuma BiotechnologyNASDAQ:PBYIAmarinNASDAQ:AMRNSilverback TherapeuticsNASDAQ:SBTXAtea PharmaceuticalsNASDAQ:AVIRView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 212,200 shares on 5/17/2024Ownership: 0.000%Walleye Trading LLCSold 8,200 shares on 5/17/2024Ownership: 0.000%Bain Capital Life Sciences Investors LLCSold 37,678 shares on 5/16/2024Ownership: 2.537%Jacobs Levy Equity Management Inc.Bought 42,449 shares on 5/16/2024Ownership: 0.077%Torno Capital LLCBought 200 shares on 5/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MRNS Stock Analysis - Frequently Asked Questions Should I buy or sell Marinus Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRNS shares. View MRNS analyst ratings or view top-rated stocks. What is Marinus Pharmaceuticals' stock price target for 2024? 7 brokerages have issued 12-month target prices for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $3.00 to $28.00. On average, they predict the company's share price to reach $13.79 in the next year. This suggests a possible upside of 828.3% from the stock's current price. View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts. How have MRNS shares performed in 2024? Marinus Pharmaceuticals' stock was trading at $10.87 on January 1st, 2024. Since then, MRNS shares have decreased by 86.3% and is now trading at $1.4850. View the best growth stocks for 2024 here. When is Marinus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our MRNS earnings forecast. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.68). The biopharmaceutical company earned $7.68 million during the quarter, compared to the consensus estimate of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative trailing twelve-month return on equity of 518.13%. What ETFs hold Marinus Pharmaceuticals' stock? ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). When did Marinus Pharmaceuticals' stock split? Marinus Pharmaceuticals's stock reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO). Who are Marinus Pharmaceuticals' major shareholders? Marinus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (7.54%), Vanguard Group Inc. (5.11%), Bain Capital Life Sciences Investors LLC (2.54%), Ikarian Capital LLC (0.00%), Hussman Strategic Advisors Inc. (0.13%) and Jacobs Levy Equity Management Inc. (0.08%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel. View institutional ownership trends. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRNS) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.